Exabis Library
Welcome to the e-CCO Library!
P404 Prolonged steroid exposure prior to admission is associated with increased likelihood of rescue therapy and colectomy in acute severe ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P404: Development of anti-drug antibodies among those treated with adalimumab and ABP 501 and its impact on serum drug concentration in randomised controlled studies
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P404: Healthcare utilization and expenditures for patients with Ulcerative Colitis on advanced therapies in Germany
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P404: Persistence of subcutaneous infliximab after switching from intravenous in a French national cohort of IBD patients in remission
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P404: Real-life experience with golimumab in ulcerative colitis patients according to prior anti-TNF use
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P404: Stopping 5-aminosalicylates in Crohn’s disease patients starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P404: Underrepresentation of minorities and lack of race reporting in ulcerative colitis drug development clinical trials
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P404: Vaccinations and immunization status in Paediatric inflammatory bowel disease: data from the VIP IBD study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P405 Comparison of long-term outcomes of infliximab vs. adalimumab in 1488 biologic-naive Korean patients with Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P405: 5-ASA prescription trends over time in inflammatory bowel disease 1996 to 2015–A UK population-based study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P405: Development and validation of a rapid immunoassay for monitoring of ustekinumab concentrations in Inflammatory Bowel Disease patients
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P405: Infliximab trough level measured during treatment induction may be predictive of the loss of response to Infliximab during treatment maintenance in inflammatory bowel disease patients: a longitudinal observational retrospective study
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P405: Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extension
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P405: Primary non-response and loss-of-response to first-line biological therapies are more common in patients with Ulcerative Colitis than Crohn’s Disease – preliminary results from the Danish IBD Biobank Project
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P405: Sustainability of biologic therapies is less in UC than CD patients independent of prior biologic experience
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P405: Toxicity of thiopurines in patients with inflammatory bowel disease: inventory and predictive factors
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P406 Adherence, acceptability and serum trough concentration of adalimumab autoinjector in quiescent patients with inflammatory bowel diseases
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P406: A retrospective analysis of the efficacy of vedolizumab on extra-intestinal manifestations in patients with inflammatory bowel disease across five European countries
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P406: AlphaE+ cells have increased expression of inflammatory markers and are correlated in the ileum and colon
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P406: Clinical correlations of infliximab trough levels and antibodies to infliximab in Korean patients with Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM